Capital Fund Management S.A. Viking Therapeutics, Inc. Transaction History
Capital Fund Management S.A.
- $33.7 Billion
- Q2 2024
A detailed history of Capital Fund Management S.A. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Capital Fund Management S.A. holds 80,809 shares of VKTX stock, worth $6.02 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
80,809
Previous 50,794
59.09%
Holding current value
$6.02 Million
Previous $4.17 Million
2.83%
% of portfolio
0.01%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding VKTX
# of Institutions
464Shares Held
65.3MCall Options Held
6.24MPut Options Held
2.97M-
Vanguard Group Inc Valley Forge, PA10.1MShares$752 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$449 Million0.01% of portfolio
-
State Street Corp Boston, MA5.12MShares$382 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.25MShares$168 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$139 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $5.71B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...